RetiredCapital BluecrossPolicy MP 1.069

Spinal cord and dorsal root ganglion stimulation

Clinical coverage policy for trial and permanent implantation of spinal cord stimulation (SCS) and dorsal root ganglion (DRG) neurostimulation for chronic neuropathic pain, describing candidate selection, required trial success, and investigational indications; applies to Capital BlueCross products with program variations noted.

Policy Summary

PayerCapital Bluecross

PolicySpinal cord and dorsal root ganglion stimulation

Policy CodePolicy MP 1.069

Change TypeRetirement review — no material changes

Effective DateRETIRED 5/1/2026

Next Review Date

Key ActionObtain and document a temporary trial demonstrating at least 50% pain relief before pursuing permanent implantation; secure prior authorization for listed device and procedure codes.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>=50%trial pain relief threshold required before permanent implantation

3-7 daystypical duration of stimulation trial

107,728FDA device reports (2016–2020)

30-40%reported incidence range of adverse events

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

ICD-10 codes listed as covered

Coverage Criteria for SCS and DRG Neurostimulation

Evidence-supported Indications (summary)

Summary of evidence supporting coverage for spinal cord stimulation (SCS), high-frequency SCS, and dorsal root ganglion (DRG) neurostimulation for treatment‑refractory chronic trunk or limb neuropathic pain:

ALL of the following

For standard spinal cord stimulation: systematic reviews and randomized controlled trials (RCTs) have been conducted; relevant outcomes include symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity.
Trials enrolling patients with underlying neuropathic pain processes have shown significant benefit; systematic reviews support use in refractory trunk or limb neuropathic pain and the body of evidence is sufficient to determine meaningful improvement in net health outcome.
For high-frequency (including 10-kHz) spinal cord stimulation: evidence includes a systematic review and multiple RCTs; relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity.
Two RCTs in SCS‑naïve patients reported clinically and statistically significant benefits; another RCT in patients previously treated with standard SCS found no benefit compared with sham control, but differences in populations and design limit comparisons. Overall evidence is sufficient to determine improvement in net health outcome.
For dorsal root ganglion neurostimulation: evidence includes a systematic review, randomized controlled trial(s), and case series; relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity.
An unblinded RCT showed higher rates of treatment success (physical functioning and quality of life) at 3 and 12 months versus standard SCS, with noninferiority for >50% pain reduction and similar serious adverse event rates; evidence is sufficient to determine improvement in net health outcome.
For other indications (e.g., critical limb ischemia, refractory angina, heart failure, cancer-related pain): available evidence is limited or inconsistent (small RCTs, case series) and is insufficient to determine that SCS improves net health outcomes.
Pooled analyses for critical limb ischemia showed mixed results for amputation risk; recent RCTs for refractory angina did not show consistent primary outcome benefits; heart failure RCTs are inconclusive; no RCTs identified for cancer-related pain.

Coding — Procedures, Devices, and Diagnoses

Covered procedure/device codesmixedCovered

C1897	Covered when medically necessary (device-related mapping shown)
C1767	Procedure code mapping (paired with L8679 / L8688 / 63688 as listed)
C1778	Procedure code mapping (paired with L8680 / L8688 / 63688 as listed)
C1787	Procedure code mapping (paired with L8681 / L8688 / 63688 as listed)
C1820	Procedure code mapping (paired with L8682 / L8688 as listed)
C1822	Procedure code mapping (paired with L8683 / L8688 as listed)
C1826	Procedure code mapping (paired with L8685 / L8688 as listed)
C1827	Procedure code mapping (paired with L8686 / L8688 as listed)
C1883	Procedure code mapping (paired with L8687 / L8688 as listed)
L8679	HCPCS mapping for specific device (listed)

1–10 of 29

1/3

Covered diagnosis (ICD-10) codesICD-10Covered

E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy
G54.0	Brachial plexus disorders

1–10 of 26

1/3

Covered ICD-10 Diagnoses (selected)ICD-10Covered

E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy
G54.0	Brachial plexus disorders

1–10 of 26

1/3

Covered ICD-10 Diagnoses (continued)ICD-10Covered

G58.0	Intercostal neuropathy
G60.0	Hereditary motor and sensory neuropathy
G60.2	Neuropathy in association with hereditary ataxia
G60.3	Idiopathic progressive neuropathy
G60.8	Other hereditary and idiopathic neuropathies
G63	Polyneuropathy in diseases classified elsewhere
G65.1	Sequelae of other inflammatory polyneuropathy
G89.0	Central pain syndrome
G89.21	Chronic pain due to trauma
G89.28	Other Chronic postprocedural pain

1–10 of 59

1/6

Device HCPCS codes mentioned in policy historyHCPCS

C1826	Device code added (document lists addition)
C1827	Device code added (document lists addition)
C1607	Device code added (document lists addition)

inv-22: Trial success threshold

Trial success thresholdDemonstration of at least 50% reduction in pain during a temporary stimulation trial is required before permanent implantation.

ApplicationApplies to temporary trials preceding permanent SCS and DRG implantation as part of medical necessity criteria.

Consequence of failureIf trial stimulation does not demonstrate ≥50% pain relief, permanent implantation would not meet documented medical necessity.

inv-23: Trial duration

Typical trial durationProviders typically perform a stimulation trial for 3 to 7 days.

Provider Actions, Prior Authorization, and Documentation

Documentation Required

Trial Requirement and Last‑Resort Criterion

A temporary trial spinal cord stimulation (SCS) or dorsal root ganglion (DRG) stimulation demonstrating at least 50% pain relief is required before permanent implantation; SCS/DRG therapies are considered last-resort treatments only after other appropriate therapies have been attempted and failed or are contraindicated.

Trial expectation: Demonstration of ≥ 50% pain relief during a temporary implanted electrode trial precedes permanent implantation.
Last-resort criterion: Treatment must be used only as a last resort after pharmacological, surgical, psychological, and physical therapies (if applicable) have been tried and failed or are judged unsuitable or contraindicated.

Prior Authorization

Prior Authorization and Coverage Determination

Prior authorization is required for SCS and DRG device implants and associated procedures. Coverage is determined when services are medically necessary and supported by the member's benefit plan and eligibility on the date of service.

Conservative Treatment Requirements Before SCS/DRG

Frequency and Re-Implantation Limits

inv-51: Not specified in this excerpt

Frequency limitsNot specified in this excerpt; policy does not provide procedural frequency limits in the cited sections.

ImplicationProviders should refer to the full policy or benefit plan for any program-specific frequency restrictions.

Coding submissionAbsence of frequency limits in this excerpt does not alter prior authorization or coding requirements noted elsewhere in the policy.

inv-52: SCS/DRG device implantation and trials

Frequency/interval notesPolicy lists SCS/DRG device implantation and trials but does not detail frequency or interval limits in the provided excerpts.

Policy history relevancePolicy history documents coding and coverage updates for device implantation and trials; consult complete policy for any frequency guidance.

Imaging and MRI Considerations

Documentation Required

Discuss MRI compatibility before permanent implant

Before permanent implantation, discuss device MRI compatibility with the patient; the policy notes MRI compatibility should be addressed but does not require specific imaging tests or intervals.

Inform the patient about MRI compatibility and the risks/benefits of implantable device types.
No specific imaging preconditions or required intervals are specified in the cited policy excerpts.

Note

Guidelines recommend trial stimulation before permanent implant

Society guidance cited in the policy recommends performing a trial stimulation prior to permanent implantation for most pain indications (except anginal pain), reinforcing the expectation to trial before implant.

Screen patients with an objective validated psychosocial instrument prior to trial, as recommended by guideline sources.
Exception noted for anginal pain where trial stimulation may not be required.

Background and Context

Background: Spinal cord stimulation (SCS) and dorsal root ganglion (DRG) neurostimulation are neuromodulation therapies used to treat chronic, treatment‑refractory neuropathic pain. SCS delivers low‑level epidural stimulation of the dorsal columns and DRG stimulation targets sensory cell bodies at the dorsal root ganglia. The policy requires a temporary trial demonstrating at least 50% pain relief before permanent implantation and treats these modalities as last‑resort options after other therapies have failed or are contraindicated.

Definitions and Key Terms

inv-42: Spinal cord stimulation (SCS)

DefinitionSpinal cord stimulation (SCS) is low‑level epidural electrical stimulation of the spinal cord dorsal columns using implanted leads and a power source to modulate neural function for pain relief.

ComponentsSCS systems include leads (4–8 electrodes), extension wires, and a power source (implantable battery or radiofrequency receiver).

Indication contextUsed for treatment‑refractory chronic trunk or limb neuropathic pain when other therapies have failed or are contraindicated.

inv-43: Dorsal root ganglion (DRG) stimulation

DefinitionDorsal root ganglion (DRG) stimulation targets the sensory cell bodies in the dorsal root ganglia via epidural access to modulate neuropathic pain transmission to the central nervous system.

Access and devices

Not Covered / Investigational Indications

NOT COVERED (policy wording identifies as investigational or insufficient evidence): the policy specifically lists SCS for critical limb ischemia to forestall amputation, SCS for refractory angina pectoris, and SCS for heart failure among indications judged investigational; cancer‑related pain is also noted as lacking sufficient evidence. The policy states insufficient or mixed evidence for these uses and does not support general coverage for them.

The document reiterates that evidence for SCS in critical limb ischemia and refractory angina is mixed or limited: Cochrane and systematic reviews and older randomized trials exist but pooled results are inconsistent, and recent RCTs for angina did not show consistent primary‑outcome benefit. Therefore these indications remain classified as investigational in the policy excerpts provided.

For refractory angina, numerous small RCTs and systematic reviews have evaluated SCS; while some studies reported benefits, several recent randomized trials failed to demonstrate significant differences in primary outcomes and the policy concludes evidence is insufficient to establish net health benefit.

Regarding heart failure, randomized trials (including an RCT in NYHA class III patients) did not find significant differences versus sham in key outcomes; the policy notes these trials may have been underpowered and concludes the evidence is insufficient to determine improvement in net health outcome for heart failure.

For cancer‑related pain, available evidence in the policy excerpts is limited to case series with no randomized controlled trials identified; the policy therefore regards evidence as insufficient to determine effects on health outcomes for cancer‑related pain.

Policy Summary

PayerCapital Bluecross

PolicySpinal cord and dorsal root ganglion stimulation

Policy CodePolicy MP 1.069

Change TypeRetirement review — no material changes

Effective DateRETIRED 5/1/2026

Next Review Date

Key ActionObtain and document a temporary trial demonstrating at least 50% pain relief before pursuing permanent implantation; secure prior authorization for listed device and procedure codes.

SourceLink

On This Page

PurposeTrial duration chosen to identify and confirm satisfactory pain relief before permanent implantation per device labeling and FDA guidance.

Patient counselingInform patients about risks and what to expect during the 3–7 day trial stimulation period.

inv-24: Clinical trial/practice expectations

Standardized outcome measuresUse validated outcome instruments (e.g., IMMPACT core domains, Oswestry Disability Index, Brief Pain Inventory) to document baseline status and response to trial stimulation.

Documentation roleOutcome measures should be included in documentation to support medical necessity and trial success assessment.

Guideline alignmentPolicy cites randomized trials, systematic reviews, and consensus guidance that reference these measures for patient selection and trial evaluation.

Prior authorization required for listed device HCPCS/CPT entries and procedure codes (see coding block).
Coverage determination is contingent on medical necessity and member benefit program/eligibility at date of service.

Denial Risk

Diagnosis Requirement and Denial Risk

Services must be supported by a qualifying ICD‑10 diagnosis included in the policy's covered diagnosis list. Claims lacking a covered ICD‑10 diagnosis listed in the policy may be at risk for denial.

Diagnosis requirement: Use one of the covered ICD‑10 codes enumerated in the policy (e.g., E10.40–E13.42, G54.x, G56.x, G57.x, G89.x, G90.x, M50.x, M51.x, M54.x, etc.).
Denial risk: Claims submitted without a covered diagnosis from the policy list may be denied.

Billing Rule

Device Coding and Code Tracking

Policy tracks and updates device and procedure codes over time; providers should reference current coding when submitting claims.

Device coding tracked: historical additions/revisions include codes C1826, C1827, and C1607 (see policy history).
Coding list: A set of HCPCS/CPT device and procedure codes are specified in the policy coding section and are subject to change.

Note

Coverage Subject to Member Benefit and Eligibility

Coverage and payment are subject to the member's benefit program, eligibility on the date of service, and a determination that the services are medically necessary and appropriate; policy statements are not guarantees of coverage or payment.

Coverage is subject to benefit limitations and exclusions in the member's contract.
Final claim processing depends on the applicable member contract and eligibility at time of service.

Step Therapy

Step Therapy Requirements

No explicit policy-level step therapy requirements are specified in this section.

The policy does not define a formal step‑therapy sequence beyond the requirement to have tried and failed other conservative/interventional therapies.
Providers should still document prior therapies and rationale for SCS/DRG as last‑resort therapy.

Documentation Required

Patient Education and Device Documentation

Provide the manufacturer's patient labeling and device education materials to the patient prior to implantation; document device manufacturer, model, and unique device identifier. Develop and document an individualized programming, treatment, and follow‑up plan.

Patient education: Deliver manufacturer's patient labeling and any other education materials before implantation.
Device documentation: Record device manufacturer, model, and unique device identifier in the medical record.
Treatment plan: Develop and document individualized programming, treatment, and follow‑up plan for SCS therapy.

Documentation Required

Required Documentation to Support Medical Necessity

Documentation must support a diagnosis of treatment‑refractory chronic neuropathic pain and evidence of attempted conservative and interventional therapies; include psychosocial screening and evaluation when applicable.

Document prior conservative therapies attempted and failed (pharmacologic, surgical, psychological, physical).
Document exhaustion of multiple conservative and interventional modalities for indications such as failed back surgery syndrome, per clinical society guidance.
Psychosocial evaluation: Screen with validated instruments (including assessment for depression) and document results as part of patient selection.

Note

Outcome Measures and Supporting Literature

Use accepted outcome measures and literature to document benefit and support medical necessity. Relevant outcome instruments include IMMPACT core domains, Oswestry Disability Index (ODI), Brief Pain Inventory, and validated mood assessments.

Outcome measures: IMMPACT recommendations, ODI, Brief Pain Inventory and validated mood/depression scales may be used to document clinical benefit.
Evidence base: Randomized controlled trials, systematic reviews, and professional society guidance (e.g., ASRA, ASIPP) support trial stimulation and are cited in the policy.

RecommendationUse full policy and benefit documents for program-specific limits when planning repeat trials or re-implantation.

Note

No specific imaging prerequisites stated

The cited policy excerpts do not specify imaging prerequisites for authorization or implant beyond discussing MRI compatibility and guideline‑based procedural imaging recommendations.

No explicit imaging prerequisites are listed in these chunks for authorization or implant.
Follow procedural imaging practices per specialty guidelines when applicable.

Note

Follow specialty guidelines for selection and procedural imaging

Practice guidelines and consensus documents are cited to guide patient selection and trial stimulation; providers should follow these guideline recommendations for appropriate patient evaluation and procedural imaging when applicable.

Refer to specialty society best‑practice and consensus guidelines for patient selection and trial stimulation.
Use guideline recommendations to inform imaging and procedural planning as appropriate.

DRG are located in the epidural space on the posterior root; at least two DRG‑targeting systems have received FDA approval or clearance.

Evidence summaryRCTs and systematic reviews cited in the policy support DRG neurostimulation for selected refractory neuropathic pain conditions.

inv-44: Treatment-refractory chronic pain

DefinitionTreatment‑refractory chronic pain refers to chronic trunk or limb pain that has not adequately responded to multiple conservative and interventional treatments and is frequently neuropathic in origin.

Common diagnosesExamples include failed back surgery syndrome, complex regional pain syndrome, arachnoiditis, radiculopathies, phantom limb/stump pain, peripheral neuropathy, and painful diabetic neuropathy.

Coverage rationaleSystematic reviews and RCTs demonstrate meaningful improvements in symptoms, function, and quality of life from SCS/DRG in these selected patients.

inv-45: Trial stimulation

DefinitionTrial stimulation is a temporary period of SCS or DRG stimulation performed to assess patient response before permanent implantation.

PurposeConducted to identify and confirm satisfactory pain relief and functional improvement to justify permanent device implantation per FDA recommendations.

Typical practiceTrials are typically performed for 3–7 days and success is commonly defined as approximately 50% reduction in pain symptoms.

inv-46: DRG neurostimulation policy history note

Policy history noteDorsal root ganglion neurostimulation was changed from investigational to medically necessary in the May 10, 2019 policy update.

ImplicationDRG stimulation is now included with SCS in the policy's medically necessary coverage criteria for selected refractory neuropathic pain.

DocumentationPolicy history records coding and rationale updates accompanying the change in coverage status; consult history for specific effective dates and coding changes.

The provided policy excerpts do not include a separate, explicit list titled 'not covered' procedures beyond the investigational indications already stated; other parts of the full policy may contain additional not‑covered language, but it is not present in these chunks.

In the chunks shown there are no explicit not‑covered procedural lists for SCS/DRG; the document instead documents investigational indications and notes areas with insufficient evidence, while administrative and coding history appear elsewhere in the policy.